Highlights
In this transportability analysis, the treatment effect observed in COAPT for mitral transcatheter edge-to-edge repair (MTEER) plus guideline-based care appeared largely preserved when projected onto contemporary U.S. practice populations drawn from the STS/ACC TVT Registry.
Among patients who would have been eligible for COAPT, the estimated 2-year absolute risk reduction with MTEER plus other COAPT interventions versus medical therapy alone was 17.0% for heart failure hospitalization and 15.4% for all-cause death.
Even in a broader real-world population of MTEER treatment candidates with secondary mitral regurgitation, regardless of strict trial eligibility, the estimated effect on heart failure hospitalization remained similar to that seen in COAPT.
The findings support external applicability of COAPT under key causal assumptions, but they do not prove that routine real-world care automatically reproduces trial outcomes without comparable medical optimization and patient selection.
Background
Secondary mitral regurgitation (SMR) remains one of the most clinically challenging manifestations of advanced left ventricular disease. In this setting, mitral valve incompetence reflects ventricular remodeling rather than primary leaflet pathology, and it often coexists with heart failure with reduced ejection fraction, recurrent congestion, reduced exercise capacity, and repeated hospitalization. Prognosis is poor, especially when significant regurgitation persists despite contemporary heart failure therapy.
The COAPT trial reshaped the field by showing that, in carefully selected symptomatic patients with moderate-to-severe or severe SMR who remained symptomatic despite maximally tolerated guideline-directed medical therapy, transcatheter edge-to-edge repair using the MitraClip device reduced heart failure hospitalization and improved survival versus medical therapy alone. However, enthusiasm was tempered by mixed evidence from other trials, especially MITRA-FR, which did not demonstrate a comparable benefit. These divergent results raised a central question for clinicians and policy makers: are COAPT’s findings broadly applicable to patients encountered in everyday U.S. practice?
This question matters because pivotal trials often enroll patients who differ meaningfully from those treated after device approval. Contemporary U.S. MTEER practice may include older patients, different ventricular geometry, different ischemic burden, varying severity of mitral regurgitation, and a wider range of comorbidity than the original trial population. A transportability analysis attempts to bridge that gap by asking what would have happened if the interventions tested in COAPT had been applied to a defined target population representative of real-world practice.
Study Design and Methods
Data sources and target populations
The investigators combined patient-level data from COAPT with real-world data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry. The TVT sample included patients treated with MTEER for secondary mitral regurgitation between March 14, 2019 and September 30, 2023.
Two clinically relevant target populations were defined. The first consisted of trial-eligible real-world patients, meaning TVT Registry patients who appeared to satisfy COAPT eligibility criteria. The second was broader and included treatment-candidate patients with SMR in U.S. practice regardless of formal trial eligibility. This second population reflects how the procedure is often considered and delivered after approval, when clinicians treat patients across a wider spectrum than that represented in a regulatory trial.
Analytic approach
The authors used inverse odds of participation weighting, a causal inference method designed to standardize trial results to the covariate distribution of an external population. Put simply, the method reweights trial participants so that the trial resembles the target population with respect to measured baseline characteristics. Once reweighted, the trial’s treatment-specific outcomes can be projected onto the target population.
This is not a simple subgroup analysis. Rather, it is an attempt to estimate how the entire package of COAPT interventions, including MTEER and the trial’s associated treatment framework such as medical therapy optimization, would perform if delivered to patients who look like those in contemporary U.S. practice.
Outcomes
The primary outcome was heart failure hospitalization at 2 years. Ten secondary outcomes were examined, including all-cause mortality. The analysis included 614 COAPT participants and 15,275 TVT Registry patients, of whom 7,289 were considered COAPT-eligible.
Assumptions underlying transportability
The validity of this method depends on several assumptions. First is conditional exchangeability across data sources, meaning that after adjustment for measured variables, trial participation itself does not carry additional prognostic information that modifies treatment effect. Second is positivity, meaning patients with a given covariate profile in the target population must have corresponding representation in the trial. Third is correct model specification and adequate measurement of key effect modifiers. These assumptions are substantial and should frame interpretation of the results.
Key Findings
Baseline differences between COAPT and contemporary U.S. practice
The analysis confirmed that COAPT patients were not identical to present-day U.S. patients receiving MTEER. Among trial-eligible TVT Registry patients, ischemic cardiomyopathy was substantially less common than in COAPT (34.1% versus 60.8%). In contrast, severe 4+ mitral regurgitation was more common in the TVT cohort (79.4% versus 47.9%). These differences are clinically important because ischemic substrate, ventricular remodeling, and regurgitation severity may all influence prognosis and procedural response.
These baseline imbalances make the study especially relevant: if benefit persists despite a markedly different covariate distribution, confidence in the broader usefulness of the COAPT strategy increases.
Primary outcome: heart failure hospitalization
In the COAPT-eligible target population, the estimated 2-year absolute risk reduction for heart failure hospitalization with MTEER plus other COAPT interventions compared with medical therapy alone was 17.0%, with a 95% confidence interval from -28.7% to -5.7%. The negative values indicate fewer events with intervention. Importantly, this effect size was similar to that estimated in the original trial, and the formal test for difference between the trial and target population was not significant.
For the broader treatment-candidate population, the estimated treatment effect on heart failure hospitalization was again similar to that in COAPT, with a reported P value for difference of 0.90. This is a notable result because it suggests that, at least for hospitalization risk, the COAPT treatment effect may extend beyond narrowly trial-defined candidates.
Secondary outcome: all-cause death
For all-cause mortality in the trial-eligible real-world population, the estimated 2-year absolute risk reduction was 15.4%, with a 95% confidence interval from -26.6% to -5.2%. Again, this was directionally and quantitatively similar to the original COAPT effect estimate, and the difference between trial and target population was not statistically significant.
From a clinical standpoint, this matters at least as much as the hospitalization endpoint. The core concern in translating structural heart interventions to practice is not simply whether procedures are technically feasible outside trials, but whether the major clinical gains, especially survival and recurrent decompensation reduction, remain intact.
What these numbers mean clinically
Absolute risk reductions of this magnitude are meaningful. In practical terms, if these estimates hold under real-world implementation of a COAPT-like care strategy, the number of patients who would need to receive the intervention package to prevent one hospitalization or death over 2 years would be relatively favorable for a high-risk heart failure population. However, one should remember that the comparison is not “device in isolation” versus usual care in today’s community settings. It is MTEER plus the broader COAPT intervention environment versus medical therapy alone as implemented in the trial.
Clinical Interpretation
Why this study is important
This study addresses a long-standing tension in structural heart disease: efficacy in an idealized trial versus effectiveness in routine care. The results suggest that the mismatch between COAPT and U.S. practice may be smaller than some critics feared, at least after accounting for measured differences in patient characteristics. That is reassuring for clinicians, health systems, and payers who have used COAPT as the evidentiary anchor for MTEER in SMR.
It also helps contextualize the apparent discordance between COAPT and MITRA-FR. The field has increasingly interpreted these trials not as irreconcilable contradictions, but as studies enrolling different phenotypes and applying different medical therapy contexts. COAPT emphasized severe regurgitation disproportionate to ventricular size in patients with optimized background therapy and favorable anatomy for clip-based repair. MITRA-FR enrolled a broader population with larger ventricles and, on average, less severe regurgitation relative to ventricular dilation. The current transportability analysis indirectly supports the idea that patient selection and treatment context, rather than geography or trial idiosyncrasy alone, drive much of the observed variation.
The critical caveat: transporting the intervention package, not only the procedure
The most important nuance in this paper is embedded in the wording of the conclusion. The authors estimate what would happen if real-world patients received the COAPT trial interventions. That phrase includes, but is not limited to, the MTEER procedure itself. COAPT involved careful site selection, echocardiographic adjudication, close follow-up, and rigorous attempts to optimize heart failure medical therapy. Therefore, the study does not justify a simplistic interpretation that all current MTEER practice will automatically reproduce COAPT-level outcomes.
For front-line clinicians, the message is that procedural referral should remain embedded within a multidisciplinary heart failure and structural heart framework. Careful review of left ventricular dimensions, symptom status, regurgitation severity, pulmonary pressures, right ventricular function, surgical options, and candidacy for advanced heart failure therapies remains essential.
Strengths
The study has several strengths. It uses patient-level trial data rather than aggregate summary estimates. It evaluates two target populations, one narrow and one broad, which improves practical relevance. The TVT Registry provides a large and contemporary real-world cohort, and the statistical framework is well suited to the question of external validity.
Limitations
The limitations are equally important. First, transportability analyses depend on measured variables; unmeasured confounding or effect modification cannot be excluded. Features such as frailty, center-level expertise, adherence to medical therapy over time, detailed ventricular mechanics, and nuanced echocardiographic findings may not have been fully captured or harmonized across datasets.
Second, positivity may be strained if segments of the real-world population are poorly represented in COAPT. In such cases, model-based extrapolation becomes less reliable. Third, registry inclusion was restricted to patients who underwent MTEER, and although the authors used the registry to define target populations, the comparison to medical therapy alone remains trial-based rather than directly observed in contemporary practice. Fourth, outcomes from COAPT reflect a specific era of heart failure therapy; uptake of newer foundational treatments, such as sodium-glucose cotransporter 2 inhibitors, may modify absolute risks and perhaps procedure selection in current practice.
Practice and Policy Implications
For heart teams, the study supports continued use of COAPT as the principal trial informing MTEER for appropriately selected patients with SMR. It also offers reassurance that real-world U.S. patients need not be identical to trial participants for benefit to remain clinically meaningful.
For policy makers and coverage bodies, the analysis provides a methodologically sophisticated argument for the external relevance of trial evidence in device-based care. This is especially valuable in cardiology, where randomized trials often have strong internal validity but uncertain generalizability. The framework used here may also be applied to other transcatheter therapies as registries mature and more linked datasets become available.
For researchers, the study underscores the need for prospective effectiveness evaluations that combine randomized and registry-based data. Future work should examine whether transportability remains stable across key subgroups, including very advanced ventricular remodeling, atrial functional mitral regurgitation, chronic kidney disease, frailty, and diverse racial and socioeconomic populations that may be underrepresented in trials.
Conclusion
This transportability analysis suggests that the benefits of COAPT are likely relevant to contemporary U.S. practice, even though real-world MTEER patients differ substantially from the original trial population. In both a COAPT-eligible cohort and a broader treatment-candidate cohort from the TVT Registry, estimated reductions in heart failure hospitalization were similar to those seen in the trial, and mortality benefit in the trial-eligible population also appeared preserved.
The most defensible clinical interpretation is not that every MTEER performed in practice will reproduce COAPT, but that COAPT’s treatment strategy appears portable when applied to comparable patients within a similarly rigorous care framework. That is an encouraging message for structural heart programs, provided enthusiasm remains coupled to disciplined patient selection, comprehensive heart failure management, and awareness of the assumptions on which these estimates rest.
Funding and ClinicalTrials.gov
The abstract provided does not report study funding details for the transportability analysis. The source trial, COAPT, was registered at ClinicalTrials.gov as NCT01626079. No ClinicalTrials.gov identifier was reported in the abstract for the transportability study itself.
References
Lalani C, Butala N, Dong H, Song Y, Stone GW, Mack MJ, Shahim B, Kazi DS, Cohen DJ, Dahabreh IJ, Yeh RW. Estimating the Effects of MTEER in U.S. Practice: A Transportability Analysis of the COAPT Trial. Journal of the American College of Cardiology. 2026-06-03. PMID: 42233929.
Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018;379:2307-2318. PMID: 30280640.
Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, Lefèvre T, Piot C, Rouleau F, Carrié D, Nejjari M, Ohlmann P, Leclercq F, Saint Etienne C, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. 2018;379:2297-2306. PMID: 30145927.
Writing Committee Members, Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145:e895-e1032. PMID: 35363499.
Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O’Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A, Toly C. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143:e72-e227. PMID: 33332150.